These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 34315043)

  • 1. Matrix metalloproteinases inhibitors in idiopathic pulmonary fibrosis: Medicinal chemistry perspectives.
    Yue L; Shi Y; Su X; Ouyang L; Wang G; Ye T
    Eur J Med Chem; 2021 Nov; 224():113714. PubMed ID: 34315043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matrix metalloproteinases as therapeutic targets for idiopathic pulmonary fibrosis.
    Craig VJ; Zhang L; Hagood JS; Owen CA
    Am J Respir Cell Mol Biol; 2015 Nov; 53(5):585-600. PubMed ID: 26121236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrix metalloproteinase: An upcoming therapeutic approach for idiopathic pulmonary fibrosis.
    Mahalanobish S; Saha S; Dutta S; Sil PC
    Pharmacol Res; 2020 Feb; 152():104591. PubMed ID: 31837390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metalloproteinases in idiopathic pulmonary fibrosis.
    Dancer RC; Wood AM; Thickett DR
    Eur Respir J; 2011 Dec; 38(6):1461-7. PubMed ID: 21700608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pivotal role of matrix metalloproteinase 13 in extracellular matrix turnover in idiopathic pulmonary fibrosis.
    Nkyimbeng T; Ruppert C; Shiomi T; Dahal B; Lang G; Seeger W; Okada Y; D'Armiento J; Günther A
    PLoS One; 2013; 8(9):e73279. PubMed ID: 24023851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum metalloproteinases 1 and 7 in the diagnosis of idiopathic pulmonary fibrosis and other interstitial pneumonias.
    Morais A; Beltrão M; Sokhatska O; Costa D; Melo N; Mota P; Marques A; Delgado L
    Respir Med; 2015 Aug; 109(8):1063-8. PubMed ID: 26174192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of Aryloxyphenyl-Heptapeptide Hybrids as Potent and Selective Matrix Metalloproteinase-2 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis.
    Takeuchi T; Hayashi M; Tamita T; Nomura Y; Kojima N; Mitani A; Takeda T; Hitaka K; Kato Y; Kamitani M; Mima M; Toki H; Ohkubo M; Nozoe A; Kakinuma H
    J Med Chem; 2022 Jun; 65(12):8493-8510. PubMed ID: 35687819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Revisiting matrix metalloproteinase 12: its role in pathophysiology of asthma and related pulmonary diseases.
    Abd-Elaziz K; Jesenak M; Vasakova M; Diamant Z
    Curr Opin Pulm Med; 2021 Jan; 27(1):54-60. PubMed ID: 33065600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matrix metalloproteinase-10: a novel biomarker for idiopathic pulmonary fibrosis.
    Sokai A; Handa T; Tanizawa K; Oga T; Uno K; Tsuruyama T; Kubo T; Ikezoe K; Nakatsuka Y; Tanimura K; Muro S; Hirai T; Nagai S; Chin K; Mishima M
    Respir Res; 2015 Sep; 16():120. PubMed ID: 26415518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matrix Metalloproteinases Retain Soluble FasL-mediated Resistance to Cell Death in Fibrotic-Lung Myofibroblasts.
    Nareznoi D; Konikov-Rozenman J; Petukhov D; Breuer R; Wallach-Dayan SB
    Cells; 2020 Feb; 9(2):. PubMed ID: 32053892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MMP expression and abnormal lung permeability are important determinants of outcome in IPF.
    McKeown S; Richter AG; O'Kane C; McAuley DF; Thickett DR
    Eur Respir J; 2009 Jan; 33(1):77-84. PubMed ID: 18829682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MMP-9 1562C>T Gene Polymorphism and Efficacy of Glucocorticoid Therapy in Idiopathic Pulmonary Fibrosis Patients.
    Zhang HT; Fang SC; Wang CY; Wang W; Wu J; Wang C; Xu B; Zhang YM
    Genet Test Mol Biomarkers; 2015 Nov; 19(11):591-7. PubMed ID: 26401883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon-γ enhances the antifibrotic effects of pirfenidone by attenuating IPF lung fibroblast activation and differentiation.
    Vu TN; Chen X; Foda HD; Smaldone GC; Hasaneen NA
    Respir Res; 2019 Sep; 20(1):206. PubMed ID: 31511015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Matrix metalloproteinase inhibitors: a patent review (2011 - 2013).
    Li NG; Tang YP; Duan JA; Shi ZH
    Expert Opin Ther Pat; 2014 Sep; 24(9):1039-52. PubMed ID: 25098768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of doxycycline on production of growth factors and matrix metalloproteinases in pulmonary fibrosis.
    Fujita H; Sakamoto N; Ishimatsu Y; Kakugawa T; Hara S; Hara A; Amenomori M; Ishimoto H; Nagata T; Mukae H; Kohno S
    Respiration; 2011; 81(5):420-30. PubMed ID: 21502778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploitation of Novel Molecular Targets to Treat Idiopathic Pulmonary Fibrosis: A Drug Discovery Perspective.
    Vaidya B; Patel R; Muth A; Gupta V
    Curr Med Chem; 2017; 24(22):2439-2458. PubMed ID: 28552057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there new hope for therapeutic matrix metalloproteinase inhibition?
    Vandenbroucke RE; Libert C
    Nat Rev Drug Discov; 2014 Dec; 13(12):904-27. PubMed ID: 25376097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sputum matrix metalloproteinase-9, tissue inhibitor of metalloprotinease-1, and their molar ratio in patients with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and healthy subjects.
    Beeh KM; Beier J; Kornmann O; Buhl R
    Respir Med; 2003 Jun; 97(6):634-9. PubMed ID: 12814147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and Structural Evolution of Matrix Metalloproteinase Inhibitors.
    Fischer T; Senn N; Riedl R
    Chemistry; 2019 Jun; 25(34):7960-7980. PubMed ID: 30720221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging therapeutic interventions for idiopathic pulmonary fibrosis.
    Chakraborty S; Chopra P; Ambi SV; Dastidar SG; Ray A
    Expert Opin Investig Drugs; 2014 Jul; 23(7):893-910. PubMed ID: 24766571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.